DALLAS, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. (Nasdaq: ASST; SATA) (“Strive” or the “Company”) today announced an increase in the dividend rate on its Variable Rate Series A Perpetual Preferred Stock (the “SATA Stock”), raising the annual dividend rate to 12.25%, up from 12.00%. The increased dividend reflects Strive’s continued commitment to enhancing shareholder value while maintaining disciplined management of its capital structure. The annual dividend rate is based on the $100 stated amount per ...

OMER, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leader in AI-powered visual sensing and Predictive Maintenance (PdM) technologies, today announced that its next generation of high-temperature sustainable optical sensors has successfully passed a series of demanding trials with a major Southeast Asian Aerospace OEM. During the evaluation, the sensor-based solution delivered high-resolution imagery of a critical component, fully immersed in oil, a notoriously challenging env ...

MONTRÉAL, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cerro de Pasco Resources Inc. (TSXV: CDPR) (OTCQB: GPPRF) (FRA: N8HP) (BVL:CDPR) (“CDPR” or the “Company”) is pleased to announce the formalization of its surface use agreement with the Community of Quiulacocha. The agreement was signed on December 11, 2025. This agreement reinforces CDPR’s long standing collaborative framework with the community and strengthens the company’s social license to operate, underscoring the constructive relationship that has supported ...

Taren Point, Australia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fitell Corporation (NASDAQ: FTEL) (“Fitell” or the “Company”) today announced the launch of 2FCulinaryAI, its first robotic product developed by its joint venture, 2F Robotics. The AI-driven robot cooking system is designed to deliver personalized and nutrition-customizable meals. 2FCulinaryAI marks the first commercial ready robotic solution produced under 2F Robotics. Targeted toward fitness and wellness conscious consumers, the product will be mar ...

Core Viewpoint - China Medical System Holdings Limited's subsidiary, Dermavon Holdings Limited, has obtained licensing rights for the innovative oral JAK1 inhibitor povorcitinib, which is aimed at treating non-segmental vitiligo and has been recognized as a Breakthrough Therapeutic Drug by the NMPA, potentially expediting its development and review process in China [1][6]. Group 1: Product Development and Clinical Trials - Povorcitinib is currently undergoing Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa, and prurigo nodularis in various countries outside China, with a Phase 2 trial for asthma also in progress [2]. - In March 2023, Incyte reported that povorcitinib met the primary endpoint in a global Phase 2b trial for non-segmental vitiligo, showing significant improvement in total body repigmentation after 24 weeks of treatment [3]. - Dermavon received approval from the NMPA in August 2025 to conduct clinical trials for povorcitinib in China, with plans to explore additional indications for skin-related diseases in the future [4]. Group 2: Market Potential and Patient Impact - Vitiligo affects approximately 10.3 million patients in China, with around 8.2 million suffering from non-segmental vitiligo, highlighting a significant unmet medical need for effective treatments [5]. - If approved, povorcitinib could offer a differentiated treatment option for non-segmental vitiligo patients, particularly those with moderate to severe forms of the disease [5]. - The inclusion of povorcitinib in the Breakthrough Therapeutic Drugs list is expected to enhance its clinical and commercial value, potentially benefiting patients with skin diseases through synergy with other Dermavon products [6]. Group 3: Collaboration and Licensing - Dermavon entered into a Collaboration and License Agreement with Incyte on March 31, 2024, granting exclusive rights to develop and commercialize povorcitinib in several regions, including Mainland China and Southeast Asia [7].

Core Insights - Jeffs' Brands Ltd is expanding into the global homeland security sector through its subsidiary KeepZone AI Inc, which has signed an exclusive distribution agreement with Zorronet Ltd to enhance its security solutions portfolio [1][2][6] Group 1: Strategic Partnership - The partnership aims to integrate Zorronet's advanced AI technology into KeepZone's offerings, creating a comprehensive security ecosystem for threat detection and response [2][6] - KeepZone has exclusive distribution rights for Zorronet's Unmanned Robotic Control Room solution in Mexico and Israel for an initial 12-month period, with potential for extension based on performance [3][6] Group 2: Technology and Applications - Zorronet's technology provides an AI-based autonomous Security Operations Center, enabling real-time monitoring and threat response with minimal human intervention [4][6] - The solution is designed for high-security applications, including critical infrastructure protection and large-scale environments [5][6] Group 3: Market Positioning - This agreement is seen as a significant expansion of KeepZone's homeland security offerings, enhancing its capabilities in the market [6][7] - Jeffs' Brands aims to leverage its data-driven operations to capitalize on the significant growth potential in the homeland security market [7]

Core Viewpoint - GlobalTech Corporation has announced the planned acquisition of 123 Investments Limited, operating as Moda in Pelle, with D. Boral Capital LLC serving as its strategic advisor for this transaction [1][2]. Company Overview - GlobalTech Corporation is a U.S.-based technology holding company focused on artificial intelligence, big data, and emerging technologies, aiming to empower innovative companies through strategic partnerships and capital investment [3]. - D. Boral Capital LLC is a global investment bank that specializes in providing strategic advisory and financial solutions to middle-market and emerging growth companies, having successfully aggregated approximately $30 billion in capital since its inception in 2020 [4][3]. Acquisition Details - The acquisition of Moda in Pelle is part of GlobalTech's strategy to scale globally and invest in cutting-edge solutions, with updates to be shared in future public filings [2]. - The transaction is subject to customary agreements and compliance, with no assurance of timely completion [2]. Moda in Pelle Overview - Moda in Pelle, established in 1975, is a British footwear brand known for its high-quality products and strong presence in the UK market, operating over 40 retail stores and a robust online platform [4].

Core Insights - Aeries Technology, Inc. has reported measurable improvements from early implementations of its Engineering Management Framework (EMF), which is now entering a phased rollout based on validated outcomes [1][2] Company Overview - Aeries Technology is a global leader in AI-enabled value creation and business transformation, particularly for private-equity portfolio companies, and has been recognized as a Great Place to Work for two consecutive years [3] Engineering Management Framework (EMF) - EMF is a governance-led system that standardizes the measurement and management of engineering performance across global delivery hubs, converting data into executive-ready insights [2] - Early programs utilizing EMF have shown significant gains in delivery predictability, release reliability, and actionable visibility into global engineering operations [2] Market Trends - Clients are increasingly prioritizing transparency, predictability, and scalable governance in their global engineering models, which is shaping the future of the Global Capability Center (GCC) market, projected to exceed $100 billion by 2030 [2] Performance Improvements - The implementation of AI-enabled engineering practices has resulted in up to 30% faster development cycles and a 30% reduction in data reconciliation timelines [5] - The framework has also facilitated faster migration cycles and improved system stability across multi-hub engineering environments [5]

Core Insights - FOXO Technologies Inc. has outlined its key milestones for 2025 and its future growth strategy, emphasizing the foundation laid in mid-2024 through acquisitions of Myrtle Recovery Centers, Inc. and Rennova Community Health, Inc. [1] - The company has expanded its healthcare portfolio with the acquisition of Vector BioSource, Inc., positioning itself as a player in the pharmaceutical services sector [4] Myrtle Recovery Centers - Myrtle Recovery Centers has established itself as a leading provider of residential and medically supervised withdrawal treatment services for substance use disorders in Tennessee since its opening in August 2023 [2] - The Oneida facility has maintained a 93% occupancy rate with an average daily census of 28, significantly up from 7.4 in 2024 [2] - Projected patient admissions for 2025 are 550, a substantial increase from 195 in 2024 [2] - Myrtle has received funding from the State of Tennessee Opioid Abatement Fund for treating uninsured patients and is developing a mobile application called "Evana" to enhance post-discharge patient care [2] Rennova Community Health - Scott County Community Hospital, also known as Big South Fork Medical Center, serves as FOXO's flagship acute care hospital, providing a range of services including inpatient, outpatient, and emergency care [3] - The hospital is projected to see over 7,000 ER patients, 3,500 outpatient visits, and 300 inpatient stays in 2025 [5] - Recently added services include swing bed and wound care, and the hospital is in-network with all major payors [5] Vector BioSource - The acquisition of Vector BioSource is expected to generate approximately $1 million in net revenues for 2025, with anticipated significant growth as the company invests in infrastructure and market expansion [4][6] - Vector specializes in sourcing biospecimens for the biotechnology and pharmaceutical research sectors [4] Corporate and Growth Outlook - The company has settled several legacy liabilities and strengthened its management team, with equity increasing from $5.3 million at the end of 2024 to $20.2 million by September 30, 2025 [7][12] - Debt has been reduced from $10.2 million at the end of 2024 to $7.1 million by September 30, 2025 [12] - FOXO has formed a wholly owned subsidiary, FOXO Acquisition Corporation, to facilitate acquisitions and has introduced a new series of preferred stock [7] - The company aims to uplist its common stock to NYSE American or another recognized exchange, although there is no certainty regarding this goal [8]

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January ...